

Elizabeth Bancroft

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5020588/elizabeth-bancroft-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21 papers	828 citations	11 h-index	23 g-index
23 ext. papers	1,089 ext. citations	6.4 avg, IF	3.13 L-index

#	Paper	IF	Citations
21	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , 2021 , 22, 1618-1631	21.7	10
20	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. <i>Current Genetic Medicine Reports</i> , 2021 , 9, 47-58	2.2	2
19	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. <i>BJU International</i> , 2021 ,	5.6	4
18	Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic mutation carriers: a case-controlled study (SIGNIFY). <i>Journal of Medical Genetics</i> , 2020 , 57, 226-236	5.8	8
17	Prostate Cancer Risk by BRCA2 Genomic Regions. <i>European Urology</i> , 2020 , 78, 494-497	10.2	2
16	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. <i>European Urology</i> , 2020 , 77, 24-35	10.2	53
15	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019 , 76, 831-842	10.2	78
14	Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. <i>BJU International</i> , 2019 , 123, 284-292	5.6	7
13	Homeobox B13 G84E Mutation and Prostate Cancer Risk. <i>European Urology</i> , 2019 , 75, 834-845	10.2	16
12	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. <i>Familial Cancer</i> , 2017 , 16, 433-440	3	39
11	Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. <i>Psycho-Oncology</i> , 2017 , 26, 1987-1993	3.9	9
10	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016 , 21, 716-22	5.7	24
9	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. <i>European Urology</i> , 2015 , 68, 186-93	10.2	192
8	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. <i>Psycho-Oncology</i> , 2015 , 24, 1492-9	3.9	17
7	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. <i>European Urology</i> , 2014 , 66, 489-99	10.2	156
6	The genetic epidemiology of prostate cancer and its clinical implications. <i>Nature Reviews Urology</i> , 2014 , 11, 18-31	5.5	162
5	Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. <i>European Journal of Radiology Open</i> , 2014 , 1, 22-27	2.6	6

4	"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. <i>Familial Cancer</i> , 2014 , 13, 625-35	3	14
3	Telomere length shows no association with BRCA1 and BRCA2 mutation status. <i>PLoS ONE</i> , 2014 , 9, e86659	3.7	7
2	How advances in genomics are changing patient care. <i>Nursing Clinics of North America</i> , 2013 , 48, 557-69	1.6	13
1	Cancer genetics: the importance of obtaining a family history. <i>Nursing Times</i> , 2006 , 102, 28-9		1